Reportlinker Adds The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities

NEW YORK, March 30 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities

http://www.reportlinker.com/p0184376/The-Future-of-Blood-Disorders-Therapeutics-Analysis-and-Market-Forecasts-to-2016---Better-and-More-Cost-Effective-Treatment-Options-Create-Opportunities.html

The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities

Summary

GBI Research has released its research - "The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities". The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global blood disorders market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets

Scope

The scope of this report includes:

- Annualized market data for the blood disorders market from 2001 to 2009, forecast forward to 2016

- Analysis of the leading therapeutic segments including anemia, thrombosis, hemophilia, neutropenia and thrombocytopenia

- Analysis of the blood disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

- Market characterization of the blood disorders market including market size, annual cost of therapy, sales volume and treatment usage patterns

- Key drivers and barriers that have a significant impact on the market

- Coverage of pipeline molecules in various phases of drug development

- Competitive benchmarking of leading companies. The key companies studied in this report are Amgen, Inc., Sanofi-Aventis, Bristol-Myers Squibb, Centocor Ortho Biotech Inc., and Baxter.

- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global blood disorders market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align product portfolio to the markets with high growth potential

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

- Develop key strategic initiatives by understanding key focus areas of leading companies

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 8

2 Global Blood Disorders Market: Introduction 11

2.1 GBI Research Report Guidance 12

3 Global Blood Disorders Market: Market Overview 13

3.1 Introduction 13

3.2 Revenue Forecasts for the Global Blood Disorders Market 14

3.2.1 Sales Value 14

3.2.2 Sales Volume 15

3.2.3 Annual Cost of Therapy 16

3.2.4 Treatment Usage Patterns 17

3.2.5 Generics' Share in the Global Blood Disorders Market 22

3.3 Blood Disorders Market Drivers 24

3.3.1 Steady Increase in the Prevalence Population, Particularly in Anemia, in the Top Five Countries in Europe 24

3.3.2 Rapid Uptake of Biologics Products due to Better Efficacy and Safety in Diseases Such as Anemia, Hemophilia and Neutropenia 24

3.3.3 Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable 24

3.3.4 Increase in Conditions Such as Cancer and Cardiovascular Events will Increase the Prevalence of Blood Disorders 25

3.4 Blood Disorders Market Restraints 25

3.4.1 Low Diagnosis Rate as the Contemporary Diagnostic Tools are Unable to Diagnose the Severe Forms of Blood Disorders 25

3.4.2 Patent Expiries of Major Blockbusters Including Plavix, Lovenox, Aranesp, Neulasta, Procrit and Others Pose a Threat to Leading Players in the Market 25

3.4.3 The Clearance of the Regulatory Pathway in the US Will Open up the World's Largest Pharmaceutical Market to Biosimilar Players 26

3.4.4 Sluggish Growth in the Annual Cost of Therapy for Blood Disorders is Expected To Drive Down the Growth Rate 26

4 Global Blood Disorders Market: Therapeutic Landscape 27

4.1 Anemia Market 27

4.1.1 Introduction 27

4.1.2 Sales Value 27

4.1.3 Sales Volume 28

4.1.4 Annual Cost of Therapy 30

4.1.5 Treatment Usage Patterns 31

4.1.6 Geographical Segmentation 36

4.1.7 Generics' Share of the Global Anemia Market 40

4.2 Thrombosis Market 42

4.2.1 Introduction 42

4.2.2 Sales Value 42

4.2.3 Sales Volume 44

4.2.4 Annual Cost of Therapy 45

4.2.5 Treatment Usage Patterns 47

4.2.6 Geographical Segmentation 52

4.2.7 Generics' Share of the Global Thrombosis Market 55

4.3 Hemophilia Market 56

4.3.1 Introduction 56

4.3.2 Sales Value 58

4.3.3 Sales Volume 59

4.3.4 Annual Cost of Therapy 60

4.3.5 Treatment Usage Patterns 62

4.3.6 Geographical Segmentation 67

4.3.7 Generics' Share in the Global Hemophilia Market 70

4.4 Neutropenia Market 72

4.4.1 Introduction 72

4.4.2 Sales Value 73

4.4.3 Sales Volume 74

4.4.4 Annual Cost of Therapy 75

4.4.5 Treatment Usage Patterns 77

4.4.6 Geographical Segmentation 82

4.4.7 Generics' Share in the Global Neutropenia Market 85

5 Global Blood Disorders Market: Geographical Landscape 88

5.1 Geographical Break-up 88

5.2 The US 91

5.2.1 Sales Value 91

5.2.2 Sales Volume 92

5.2.3 Annual Cost of Therapy 93

5.2.4 Treatment Usage Patterns 94

5.3 Top Five Countries in Europe 98

5.3.1 Sales Value 98

5.3.2 Sales Volume 100

5.3.3 Annual Cost of Therapy 101

5.3.4 Treatment Usage Patterns 103

5.4 Japan 107

5.4.1 Sales Value 107

5.4.2 Sales Volume 108

5.4.3 Annual Cost of Therapy 110

5.4.4 Treatment Usage Patterns 111

6 Global Blood Disorders Market: Pipeline Analysis 115

6.1 Introduction 115

6.1.1 Research and Development Pipeline – Anemia 116

6.1.2 Research and Development Pipeline – Thrombosis 117

6.1.3 Research and Development Pipeline – Hemophilia 117

6.1.4 Research and Development Pipeline – Neutropenia 118

6.2 Profiles of Key Late-Stage Drugs in the Blood Disorders Market 119

6.2.1 Xarelto 119

6.2.2 AVE-5026 120

6.2.3 Apixaban 121

6.2.4 Hematide 121

6.2.5 MAXY–G34 122

7 Global Blood Disorders Market: Competitive Landscape 123

7.1 Market Share Analysis: Blood Disorders 123

7.2 Competitive Profiling 124

7.2.1 Amgen 124

7.2.2 Sanofi-Aventis 126

7.2.3 Bristol-Myers Squibb 126

7.2.4 Centocor Ortho Biotech Inc. 127

7.2.5 Baxter 128

8 Global Blood Disorders Market: Strategic Consolidations 129

8.1 Overview 129

8.1.1 GlaxoSmithKline Acquired JCR Pharmaceuticals Co Ltd. in December 2009 130

8.1.2 Biovitrum AB Acquired Swedish Orphan International AB in November 2009 131

8.1.3 LFB Biotechnologies Acquired GTC Biotherapeutics Inc in November 2009 131

8.1.4 Watson Pharmaceuticals Acquired Arrow Group in June 2009 131

8.1.5 Sanofi-Aventis SA Acquired Medley Pharmaceuticals in April 2009 131

8.1.6 Merck & Co. Acquired Insmed Corporation in February 2009 132

8.1.7 Pfizer Acquired Wyeth in January 2009 132

8.2 R&D Licensing Agreements 132

8.2.1 Deals by Indication 132

8.2.2 Deals by Phase 133

8.2.3 Deals by Geography 133

8.2.4 Deals by Licensing Type 134

8.2.5 Deals by Value ($) 135

8.2.6 Preclinical 135

8.2.7 Phase II 136

8.2.8 Phase III 138

8.2.9 Filed/Approved 139

9 Global Blood Disorders Market: Appendix 140

9.1 Market Definitions 140

9.2 Abbreviations 140

9.3 Research Methodology 141

9.3.1 Coverage 141

9.3.2 Secondary Research 142

9.3.3 Primary Research 142

9.3.4 Forecasts 142

9.3.5 Expert Panel Validation 144

9.4 Contact Us 145

9.5 Disclaimer 145

9.6 Sources 145

1.1 List of Tables

Table 1: Blood Disorders Market, Global, Sales Value ($bn), 2001–2009 14

Table 2: Blood Disorders Market, Global, Sales Value ($bn), 2009–2016 15

Table 3: Blood Disorders Market, Global, Sales Volume, billion, 2001–2009 16

Table 4: Blood Disorders Market, Global, Sales Volume, billion, 2009–2016 16

Table 5: Blood Disorders Market, Global, Annual Cost of Therapy ($), 2001–2009 17

Table 6: Blood Disorders Market, Global, Annual Cost of Therapy ($), 2009–2016 17

Table 7: Blood Disorders Market, Global, Treatment Usage Patterns, 2001–2009 18

Table 8: Blood Disorders Market, Global, Treatment Usage Patterns, 2009–2016 18

Table 9: Blood Disorders Market, Global, Branded v/s Generic Drugs, $bn, 2001–2009 23

Table 10: Blood Disorders Market, Global, Branded v/s Generic Drugs, $bn, 2009–2016 23

Table 11: Blood Disorders Market, Global, Anemia Sales Value ($bn), 2001–2009 28

Table 12: Blood Disorders Market, Global, Anemia Sales Value ($bn), 2009–2016 28

Table 13: Blood Disorders Market, Global, Anemia Sales Volume (billion), 2001–2009 29

Table 14: Blood Disorders Market, Global, Anemia Sales Volume (billion), 2009–2016 29

Table 15: Blood Disorders Market, Global, Anemia Annual Cost of Therapy ($), 2001–2009 30

Table 16: Blood Disorders Market, Global, Anemia Annual Cost of Therapy ($), 2009–2016 30

Table 17: Blood Disorders Market, Global, Anemia Treatment Usage Patterns (million),

2001–2009 32

Table 18: Blood Disorders Market, Global, Anemia Treatment Usage Patterns (million),

2009–2016 32

Table 19: Blood Disorders Market, Global, Anemia Market Geographical Segmentation,

2001–2009 39

Table 20: Blood Disorders Market, Global, Anemia Market Geographical Segmentation,

2009–2016 39

Table 21: Blood Disorders Market, Global, Anemia Branded Vs Generics, 2001–2009 41

Table 22: Blood Disorders Market, Global, Anemia Branded Vs Generics, 2009–2016 41

Table 23: Blood Disorders Market, Global, Thrombosis Sales Value ($bn), 2001–2009 43

Table 24: Blood Disorders Market, Global, Thrombosis Sales Value ($bn), 2009–2016 43

Table 25: Blood Disorders Market, Global, Thrombosis Sales Volume (billion), 2001–2009 45

Table 26: Blood Disorders Market, Global, Thrombosis Sales Volume (billion), 2009–2016 45

Table 27: Blood Disorders Market, Global, Thrombosis Annual Cost of Therapy ($), 2001–2009 46

Table 28: Blood Disorders Market, Global, Thrombosis Annual Cost of Therapy ($), 2009–2016 46

Table 29: Blood Disorders Market, Global, Thrombosis Treatment Usage Patterns (million), 2001–2009 47

Table 30: Blood Disorders Market, Global, Thrombosis Treatment Usage Patterns (million), 2009–2016 48

Table 31: Blood Disorders Market, Global, Thrombosis Market Geographical Segmentation, 2001–2009 53

Table 32: Blood Disorders Market, Global, Thrombosis Market Geographical Segmentation, 2009–2016 54

Table 33: Blood Disorders Market, Global, Thrombosis Branded Vs Generics, 2001–2009 55

Table 34: Blood Disorders Market, Global, Thrombosis Branded Vs Generics, 2009–2016 56

Table 35: Blood Disorders Market, Global, Hemophilia Sales Value ($bn), 2001–2009 58

Table 36: Blood Disorders Market, Global, Hemophilia Sales Value ($bn), 2009–2016 58

Table 37: Blood Disorders Market, Global, Hemophilia Sales Volume (million), 2001–2009 59

Table 38: Blood Disorders Market, Global, Hemophilia Sales Volume (million), 2009–2016 59

Table 39: Blood Disorders Market, Global, Hemophilia Annual Cost of Therapy ($), 2001–2009 60

Table 40: Blood Disorders Market, Global, Hemophilia Annual Cost of Therapy ($), 2009–2016 61

Table 41: Blood Disorders Market, Global, Hemophilia Treatment Usage Patterns (000s),

2001–2009 62

Table 42: Blood Disorders Market, Global, Hemophilia Treatment Usage Patterns (000s),

2009–2016 62

Table 43: Blood Disorders Market, Global, Hemophilia Market Geographical Segmentation, 2001–2009 69

Table 44: Blood Disorders Market, Global, Hemophilia Market Geographical Segmentation, 2009–2016 69

Table 45: Blood Disorders Market, Global, Hemophilia Branded Vs Generics, 2001–2009 71

Table 46: Blood Disorders Market, Global, Hemophilia Branded Vs Generics, 2009–2016 71

Table 47: Blood Disorders Market, Global, Neutropenia Sales Value ($bn), 2001–2009 74

Table 48: Blood Disorders Market, Global, Neutropenia Sales Value ($bn), 2009–2016 74

Table 49: Blood Disorders Market, Global, Neutropenia Sales Volume (million), 2001–2009 75

Table 50: Blood Disorders Market, Global, Neutropenia Sales Volume (million), 2009–2016 75

Table 51: Blood Disorders Market, Global, Neutropenia Annual Cost of Therapy ($), 2001–2009 76

Table 52: Blood Disorders Market, Global, Neutropenia Annual Cost of Therapy ($), 2001–2016 76

Table 53: Blood Disorders Market, Global, Neutropenia Treatment Usage Patterns (million), 2001–2009 77

Table 54: Blood Disorders Market, Global, Neutropenia Treatment Usage Patterns (million), 2009–2016 78

Table 55: Blood Disorders Market, Global, Neutropenia Market Geographical Segmentation, 2001–2009 84

Table 56: Blood Disorders Market, Global, Neutropenia Market Geographical Segmentation, 2009–2016 84

Table 57: Blood Disorders Market, Global, Neutropenia Branded Vs Generics, 2001–2009 86

Table 58: Blood Disorders Market, Global, Neutropenia Branded Vs Generics, 2009–2016 86

Table 59: Blood Disorders Market, Global, Sales Value by Geography ($bn), 2001–2009 89

Table 60: Blood Disorders Market, Global, Sales Value by Geography ($bn), 2009–2016 89

Table 61: Blood Disorders Market, US, Sales Value ($bn), 2001–2009 91

Table 62: Blood Disorders Market, US, Sales Value ($bn), 2009–2016 91

Table 63: Blood Disorders Market, US, Sales Volume (billion), 2001–2009 92

Table 64: Blood Disorders Market, US, Sales Volume (billion), 2009–2016 92

Table 65: Blood Disorders Market, US, Annual Cost of Therapy ($), 2001–2009 93

Table 66: Blood Disorders Market, US, Annual Cost of Therapy ($), 2009–2016 93

Table 67: Blood Disorders Market, US, Treatment Usage Patterns (millions), 2001–2009 95

Table 68: Blood Disorders Market, US, Treatment Usage Patterns (millions), 2009–2016 95

Table 69: Blood Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2009 99

Table 70: Blood Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2009–2016 99

Table 71: Blood Disorders Market, Top Five Countries in Europe, Sales Volume (billion),

2001–2009 101

Table 72: Blood Disorders Market, Top Five Countries in Europe, Sales Volume (billion),

2009–2016 101

Table 73: Blood Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2009 102

Table 74: Blood Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009–2016 102

Table 75: Blood Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2001–2009 103

Table 76: Blood Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2009–2016 104

Table 77: Blood Disorders Market, Japan, Sales Value ($bn), 2001–2009 108

Table 78: Blood Disorders Market, Japan, Sales Value ($bn), 2009–2016 108

Table 79: Blood Disorders Market, Japan, Sales Volume (billion), 2001–2009 109

Table 80: Blood Disorders Market, Japan, Sales Volume (billion), 2009–2016 109

Table 81: Blood Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2009 110

Table 82: Blood Disorders Market, Japan, Annual Cost of Therapy ($), 2009–2016 110

Table 83: Blood Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2009 111

Table 84: Blood Disorders Market, Japan, Treatment Usage Pattern (million), 2009–2016 112

Table 85: Blood Disorders Market, Global, Major M&A Deals, 2009 130

Table 86: Blood Disorders Market, Global, Licensing Agreements for Drugs in the Preclinical Stage (%), 2009–2010 135

Table 87: Blood Disorders Market, Global, Licensing Agreements for Drugs in the Phase II Stage, 2009–2010 137

Table 88: Blood Disorders Market, Global, Licensing Agreements for Drugs in the Phase III Stage, 2009–2010 138

Table 89: Blood Disorders Market, Global, Licensing Agreements for Drugs in the Filed/Approved Stage, 2009–2010 139

1.2 List of Figures

Figure 1: Blood Disorders Market, Global, Drivers and Restraints, 2009 13

Figure 2: Blood Disorders Market, Global, Sales Value ($bn), 2001–2016 14

Figure 3: Blood Disorders Market, Global, Sales Volume, billion, 2001–2016 15

Figure 4: Blood Disorders Market, Global, Annual Cost of Therapy ($), 2001–2016 16

Figure 5: Blood Disorders Market, Global, Therapeutic Usage Patterns, 2001–2016 17

Figure 6: Blood Disorders Market, Global, Diseases Population (million), 2001–2016 19

Figure 7: Blood Disorders Market, Global, Treatment Seeking Population (million), 2001–2016 20

Figure 8: Blood Disorders Market, Global, Diagnosed Population (million), 2001–2016 21

Figure 9: Blood Disorders Market, Global, Prescription Population (million), 2001–2016 22

Figure 10: Blood Disorders Market, Global, Branded v/s Generic Drugs, $bn, 2001–2016 23

Figure 11: Blood Disorders Market, Global, Market Indicators, 2009 24

Figure 12: Blood Disorders Market, Global, Anemia Sales Value ($bn), 2001–2016 28

Figure 13: Blood Disorders Market, Global, Anemia Sales Volume (billion), 2001–2016 29

Figure 14: Blood Disorders Market, Global, Anemia Annual Cost of Therapy ($), 2001–2016 30

Figure 15: Blood Disorders Market, Global, Anemia Treatment Usage Patterns (million),

2001–2016 31

Figure 16: Blood Disorders Market, Global, Anemia Diseased Population (million), 2001–2016 33

Figure 17: Blood Disorders Market, Global, Anemia Treatment Seeking Population (million), 2001–2016 34

Figure 18: Blood Disorders Market, Global, Anemia Diagnosis Population (million), 2001–2016 35

Figure 19: Blood Disorders Market, Global, Anemia Prescription Population (million), 2001–2016 36

Figure 20: Blood Disorders Market, Global, Anemia Market Segmentation by Geography, 2009 and 2016 37

Figure 21: Blood Disorders Market, Global, Anemia Market in the Top Five Countries in Europe, 2009 and 2016 37

Figure 22: Blood Disorders Market, Global, Anemia Market Geographical Segmentation,

2001–2016 38

Figure 23: Blood Disorders Market, Global, Anemia Market, Geography Benchmarking, 2009 40

Figure 24: Blood Disorders Market, Global, Anemia Branded Vs Generics, 2001–2016 41

Figure 25: Blood Disorders Market, Global, Anemia Market, Generics Share, 2009 and 2016 42

Figure 26: Blood Disorders Market, Global, Thrombosis Sales Value ($bn), 2001–2016 43

Figure 27: Blood Disorders Market, Global, Thrombosis Sales Volume (billion), 2001–2016 44

Figure 28: Blood Disorders Market, Global, Thrombosis Annual Cost of Therapy ($), 2001–2016 46

Figure 29: Blood Disorders Market, Global, Thrombosis Treatment Usage Patterns (million), 2001–2016 47

Figure 30: Blood Disorders Market, Global, Thrombosis Diseased Population (million), 2001–2016 48

Figure 31: Blood Disorders Market, Global, Thrombosis Treatment Seeking Population (million), 2001–2016 49

Figure 32: Blood Disorders Market, Global, Thrombosis Diagnosis Population (million),

2001–2016 50

Figure 33: Blood Disorders Market, Global, Thrombosis Prescription Population (million),

2001–2016 51

Figure 34: Blood Disorders Market, Global, Thrombosis Market Segmentation by Geography, 2009 and 2016 52

Figure 35: Blood Disorders Market, Global, Thrombosis Market in the Top Five Countries in Europe, 2009 and 2016 52

Figure 36: Blood Disorders Market, Global, Thrombosis Market Geographical Segmentation, 2001–2016 53

Figure 37: Blood Disorders Market, Global, Thrombosis Market, Geography Benchmarking, 2009 54

Figure 38: Blood Disorders Market, Global, Thrombosis Branded Vs Generics, 2001–2016 55

Figure 39: Blood Disorders Market, Global, Thrombosis Market, Generics Share, 2009 and 2016 56

Figure 40: Hemophilia – Disease Cause, 2010 57

Figure 41: Blood Disorders Market, Global, Hemophilia Sales Value ($bn), 2001–2016 58

Figure 42: Blood Disorders Market, Global, Hemophilia Sales Volume (million), 2001–2016 59

Figure 43: Blood Disorders Market, Global, Hemophilia Annual Cost of Therapy ($), 2001–2016 60

Figure 44: Blood Disorders Market, Global, Hemophilia Treatment Usage Patterns (000s),

2001–2016 62

Figure 45: Blood Disorders Market, Global, Hemophilia Diseased Population (000s), 2001–2016 63

Figure 46: Blood Disorders Market, Global, Hemophilia Treatment Seeking Population (000s), 2001–2016 64

Figure 47: Blood Disorders Market, Global, Hemophilia Diagnosis Population (000s), 2001–2016 65

Figure 48: Blood Disorders Market, Global, Hemophilia Prescription Population (000s),

2001–2016 66

Figure 49: Blood Disorders Market, Global, Hemophilia Market Segmentation by Geography, 2009 and 2016 67

Figure 50: Blood Disorders Market, Global, Hemophilia Market in the Top Five Countries in Europe, 2009 and 2016 67

Figure 51: Blood Disorders Market, Global, Hemophilia Market Geographical Segmentation, 2001–2016 68

Figure 52: Blood Disorders Market, Global, Hemophilia Market, Geography Benchmarking, 2009 70

Figure 53: Blood Disorders Market, Global, Hemophilia Branded Vs Generics, 2001–2016 71

Figure 54: Blood Disorders Market, Global, Hemophilia Market, Generics Share, 2009 and 2016 72

Figure 55: Blood Disorders Market, Global, Neutropenia Sales Value ($bn), 2001–2016 73

Figure 56: Blood Disorders Market, Global, Neutropenia Sales Volume (million), 2001–2016 74

Figure 57: Blood Disorders Market, Global, Neutropenia Annual Cost of Therapy ($), 2001–2016 76

Figure 58: Blood Disorders Market, Global, Neutropenia Treatment Usage Patterns (million), 2001–2016 77

Figure 59: Blood Disorders Market, Global, Neutropenia Diseased Population (million),

2001–2016 79

Figure 60: Blood Disorders Market, Global, Neutropenia Treatment Seeking Population (million), 2001–2016 80

Figure 61: Blood Disorders Market, Global, Neutropenia Diagnosed Population (million),

2001–2016 81

Figure 62: Blood Disorders Market, Global, Neutropenia Prescription Population (million),

2001–2016 82

Figure 63: Blood Disorders Market, Global, Neutropenia Market Segmentation by Geography, 2009 and 2016 82

Figure 64: Blood Disorders Market, Global, Neutropenia Market in the Top Five Countries in Europe (%), 2009 and 2016 83

Figure 65: Blood Disorders Market, Global, Neutropenia Market Geographical Segmentation, 2001–2016 84

Figure 66: Blood Disorders Market, Global, Neutropenia Market, Geography Benchmarking, 2009 85

Figure 67: Blood Disorders Market, Global, Neutropenia Branded Vs Generics, 2001–2016 86

Figure 68: Blood Disorders Market, Global, Neutropenia Market, Generics Share, 2009 and 2016 87

Figure 69: Blood Disorders Market, Global, Market Share by Geography, 2009 and 2016 88

Figure 70: Blood Disorders Market, Global, Sales Value by Geography ($bn), 2001–2016 88

Figure 71: Blood Disorders Market, Global, Geography Benchmarking, 2009 and 2016 90

Figure 72: Blood Disorders Market, US, Sales Value ($bn), 2001–2016 91

Figure 73: Blood Disorders Market, US, Sales Volume (billion), 2001–2016 92

Figure 74: Blood Disorders Market, US, Annual Cost of Therapy ($), 2001–2016 93

Figure 75: Blood Disorders Market, US, Treatment Usage Patterns (millions), 2001–2016 94

Figure 76: Blood Disorders Market, US, Diseased Population (millions), 2001–2016 95

Figure 77: Blood Disorders Market, US, Treatment Seeking Population (millions), 2001–2016 96

Figure 78: Blood Disorders Market, US, Diagnosed Population (millions), 2001–2016 97

Figure 79: Blood Disorders Market, US, Prescription Population (millions), 2001–2016 98

Figure 80: Blood Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2016 99

Figure 81: Blood Disorders Market, Top Five Countries in Europe, Sales Volume (billion),

2001–2016 100

Figure 82: Blood Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2016 102

Figure 83: Blood Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2001–2016 103

Figure 84: Blood Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2001–2016 105

Figure 85: Blood Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2001–2016 105

Figure 86: Blood Disorders Market, Top Five Countries in Europe, Diagnosed Population (million), 2001–2016 106

Figure 87: Blood Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2001–2016 107

Figure 88: Blood Disorders Market, Japan, Sales Value ($bn), 2001–2016 108

Figure 89: Blood Disorders Market, Japan, Sales Volume (billion), 2001–2016 109

Figure 90: Blood Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2016 110

Figure 91: Blood Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2016 111

Figure 92: Blood Disorders Market, Japan, Diseased Population (million), 2001–2016 112

Figure 93: Blood Disorders Market, Japan, Treatment Seeking Population (million), 2001–2016 113

Figure 94: Blood Disorders Market, Japan, Diagnosed Population (million), 2001–2016 114

Figure 95: Blood Disorders Market, Japan, Prescription Population (million), 2001–2016 114

Figure 96: Blood Disorders Market, Global, R&D Pipeline by Indication (%), March 2010 115

Figure 97: Blood Disorders Market, Global, R&D Pipeline by Phase (%), March 2010 116

Figure 98: Blood Disorders Market, Global, R&D Pipeline by Phase in Anemia Market (%),

March 2010 116

Figure 99: Blood Disorders Market, Global, R&D Pipeline by Phase in Thrombosis Market (%), March 2010 117

Figure 100: Blood Disorders Market, Global, R&D Pipeline by Phase in Hemophilia Market (%), March 2010 118

Figure 101: Blood Disorders Market, Global, R&D Pipeline by Phase in Neutropenia Market (%), March 2010 119

Figure 102: Blood Disorders Market, Global, Market Share of Top Manufacturers (%), 2008 123

Figure 103: Blood Disorders Market, Global, Revenue of Top Six Players ($m), 2006–2008 123

Figure 104: Blood Disorders Market, Global, Competitive Analysis of Top Five Players, Market Share and CAGR (%), 2006–2008 124

Figure 105: Blood Disorders Market, Global, M&A Deals by Indication (%), 2009 129

Figure 106: Blood Disorders Market, Global, Major Licensing Agreements By Indication (%),

2009–2010 132

Figure 107: Blood Disorders Market, Global, Major Licensing Agreements By Phase (%),

2009–2010 133

Figure 108: Blood Disorders Market, Global, Major Licensing Agreements By Geography (%), 2009–2010 133

Figure 109: Blood Disorders Market, Global, Major Licensing Agreements By Licensing Type (%), 2009–2010 134

Figure 110: Blood Disorders Market, Global, Major Licensing Agreements By Deal Value (%), 2009–2010 135

Figure 111: GBI Research Methodology 141

Figure 112: GBI Research Market Forecasting Model 144

Companies mentioned

Amgen

Sanofi-Aventis

Bristol-Myers Squibb

Centocor Ortho Biotech Inc

Baxter

To order this report:

Healthcare Industry: The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker